List view / Grid view
26 November 2013 | By Boehringer Ingelheim
The application for European marketing authorisation of faldaprevir* has been fully validated and granted accelerated assessment by the European Medicines Agency...
22 November 2013 | By Novo Nordisk
Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart...
22 November 2013 | By Biogen Idec
This designation will provide 10 years of regulatory exclusivity for TECFIDERA in the European Union...
22 November 2013 | By AstraZeneca
Xigduo™ combines dapagliflozin (tradename Forxiga®), a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride in a twice daily tablet...
21 November 2013 | By GlaxoSmithKline
“We welcome the CHMP’s positive opinion on dolutegravir – it puts us a step closer to offering this new treatment option to people across Europe who are living with HIV...”
18 November 2013 | By Merck
Marketing authorization application also filed with the European Medicines Agency...
2 July 2013 | By Nova Laboratories Ltd
The European Medicines Agency has approved an extension of the in-use shelf life for Xaluprine...
22 February 2013 | By Sanofi
The EMA recommended market approval for Sanofi Pasteur’s 6-in-1 pediatric vaccine...
16 November 2012 | By Novartis
The CHMP of the EMA adopted a positive opinion for Exjade®...
16 November 2012 | By Novartis
The CHMP of the EMA has adopted a positive opinion for Bexsero for use in individuals from 2 months of age and older...
16 November 2012 | By Roche
The continued use of Avastin based therapy beyond first progression in metastatic colorectal cancer patients leads to survival benefits...
19 July 2012 | By Pfizer
The EMA has accepted for review the MAA for bazedoxifene/conjugated estrogens...
9 July 2012 | By European Medicines Agency (EMA)
The EMA has been notified by Sanofi-aventis of its decision to withdraw its marketing authorisation application for Mulsevo...
3 July 2012 | By FTI Consulting
The European Commission has adopted a legally binding decision in favour of granting of marketing authorisations for flutiform®...
22 June 2012 | By Novartis
Positive opinion for Afinitor® tablets...
